Japan · Delayed Price · Currency is JPY Kidswell Bio Statistics
Total Valuation
Kidswell Bio has a market cap or net worth of JPY 7.34 billion. The enterprise value is 6.60 billion.
| Market Cap | 7.34B |
| Enterprise Value | 6.60B |
Important Dates
The last earnings date was Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kidswell Bio has 49.62 million shares outstanding. The number of shares has increased by 20.48% in one year.
| Current Share Class | 49.62M |
| Shares Outstanding | 49.62M |
| Shares Change (YoY) | +20.48% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 5.07% |
| Owned by Institutions (%) | -5.06% |
| Float | 34.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.67 |
| PS Ratio | 1.11 |
| PB Ratio | 4.45 |
| P/TBV Ratio | 4.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.98 |
| EV / Sales | 1.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.93 |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 1.54.
| Current Ratio | 2.72 |
| Quick Ratio | 1.94 |
| Debt / Equity | 1.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.29 |
| Interest Coverage | -2.84 |
Financial Efficiency
Return on equity (ROE) is -26.98% and return on invested capital (ROIC) is -16.62%.
| Return on Equity (ROE) | -26.98% |
| Return on Assets (ROA) | -1.33% |
| Return on Invested Capital (ROIC) | -16.62% |
| Return on Capital Employed (ROCE) | -3.53% |
| Weighted Average Cost of Capital (WACC) | 8.12% |
| Revenue Per Employee | 178.08M |
| Profits Per Employee | -11.16M |
| Employee Count | 37 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 5.51 |
Taxes
In the past 12 months, Kidswell Bio has paid 11.00 million in taxes.
| Income Tax | 11.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.80% in the last 52 weeks. The beta is 1.12, so Kidswell Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -34.80% |
| 50-Day Moving Average | 222.62 |
| 200-Day Moving Average | 243.51 |
| Relative Strength Index (RSI) | 20.19 |
| Average Volume (20 Days) | 703,840 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kidswell Bio had revenue of JPY 6.59 billion and -413.00 million in losses. Loss per share was -8.46.
| Revenue | 6.59B |
| Gross Profit | 1.52B |
| Operating Income | -139.00M |
| Pretax Income | -402.00M |
| Net Income | -413.00M |
| EBITDA | n/a |
| EBIT | -139.00M |
| Loss Per Share | -8.46 |
Balance Sheet
The company has 3.29 billion in cash and 2.55 billion in debt, with a net cash position of 745.00 million or 15.01 per share.
| Cash & Cash Equivalents | 3.29B |
| Total Debt | 2.55B |
| Net Cash | 745.00M |
| Net Cash Per Share | 15.01 |
| Equity (Book Value) | 1.65B |
| Book Value Per Share | 33.31 |
| Working Capital | 3.69B |
Cash Flow
In the last 12 months, operating cash flow was -1.10 billion and capital expenditures -17.00 million, giving a free cash flow of -1.11 billion.
| Operating Cash Flow | -1.10B |
| Capital Expenditures | -17.00M |
| Depreciation & Amortization | n/a |
| Net Borrowing | 1.09B |
| Free Cash Flow | -1.11B |
| FCF Per Share | -22.43 |
Margins
Gross margin is 23.11%, with operating and profit margins of -2.11% and -6.27%.
| Gross Margin | 23.11% |
| Operating Margin | -2.11% |
| Pretax Margin | -6.10% |
| Profit Margin | -6.27% |
| EBITDA Margin | n/a |
| EBIT Margin | -2.11% |
| FCF Margin | n/a |
Dividends & Yields
Kidswell Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.48% |
| Shareholder Yield | -20.48% |
| Earnings Yield | -5.62% |
| FCF Yield | -15.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Kidswell Bio has an Altman Z-Score of 2.98 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 1 |